Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

NCT05752136 | Recruiting Phase 3

• 1 other identifier: LXSHYJ-20221129-02
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

Short-course radiotherapy combined with immunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for locally advanced rectal cancer.In view of the shortcomings of the current preoperative neoadjuvant treatment model for locally advanced rectal cancer, we will explore the feasibility of a new model of short-course radiotherapy combined with immunotherapy, and develop a possible optimal plan based on the existing theoretical basis, namely "short-course radiotherapy + PD-L1 monoclonal antibody combined with CAPEOX chemotherapy for 2 cycles", and explore the efficacy and adverse effects of this model. The study will also attempt to explore the characteristics of the treatment beneficiary population, explore the characteristics of the treatment beneficiary population by multi-dimensional tumor and microenvironmental information through multi-omics sequencing analysis, attempt to build an efficacy prediction model, early screening of the treatment beneficiary population for precise treatment, and thus explore a new model of radiotherapy combined with immunotherapy.

Conditions

Rectal Cancer

Outcome Measures

Primary Outcomes (1)

• pCR rate

  The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX

  Up to 10 weeks (once surgery is done) ]

Secondary Outcomes (6)

• Tumor regression grade

  Up to 10 weeks (once surgery is done)

• OS

  Up to 3 years

• PFS

  Up to 3 years

• TRAEs

  Up to 3 years

• Surgical Complications

  Up to 24 weeks

Study Arms (2)

Neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision

EXPERIMENTAL

Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW). Other Name: KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1 Drug: Capecitabine 1000mg/m2，po，bid，d1-14 Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days. Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.

Biological: Envafolimab

Neoadjuvant chemoradiotherapy and total mesorectal excision

NO INTERVENTION

Drug: Oxaliplatin 130mg/m2，ivgtt，d1 Drug: Capecitabine 1000mg/m2，po，bid，d1-14 Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days. Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.

Interventions

Envafolimab BIOLOGICAL

This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).

Neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who are willing to receive neoadjuvant therapy.
• ≧18 years old.
• Diagnosed by digital rectal examination, colonoscopy, and high-resolution MRI of the pelvis, the tumor is less than or equal to 12 cm from the anus.
• Histologically diagnosed as rectal adenocarcinoma.
• The clinical staging by pelvic contrast-enhanced CT and pelvic high-resolution MRI were cT2-4a N+, cT3/T4a N0.
• MMR protein detection or MSI gene detection of rectal cancer specimens confirmed pMMR or MSS before treatment .
• The patient has good compliance and can come to the hospital for re-examination as required.
• ECOG Scale of Performance Status score 0-1 point.
• Have not received anti-tumor and immunotherapy before enrollment.
• Laboratory inspections must meet the following standards:
• White blood cell count\>3.5×109/L, absolute value of neutrophils\>1.8×109/L, platelet count ≥75×109/L, hemoglobin ≥100g/L;
• INR≤1.5, and APTT≤1.5 times the upper limit of normal or partial prothrombin time (PT) ≤1.5 times the upper limit of normal;
• Total bilirubin ≤ 1.25 times the upper limit of normal; ALT and AST \< 5 times the upper limit of normal;
• h creatinine clearance \>50mL/min or serum creatinine \<1.5 times the upper limit of normal.
• Voluntarily participate in this study and sign the informed consent.

You may not qualify if:

• History of other malignant diseases in the past 5 years.
• Patients with metastases from other sites (stage IV patients).
• Patients with clinical staging of T1-2N0 or T4b, or positive lateral lymph nodes by pelvic contrast-enhanced CT and pelvic high-resolution MRI.
• Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. requiring emergency surgery.
• Known allergic to oxaliplatin, capecitabine, PD-L1 monoclonal antibody and other drugs.
• Pathologically suggested signet ring cell carcinoma and mucinous adenocarcinoma.
• dMMR or MSI-H patients.
• The patient is accompanied by any unstable systemic disease, including but not limited to: severe infection, uncontrolled diabetes, hypertension uncontrolled by medication, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardial Infarction, congestive heart failure, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease; disease affecting the patient's life.
• The disease (such as mental illness, etc.) or condition (such as alcoholism or drug abuse, etc.) associated with the patient will increase the risk of the patient receiving the trial drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results.
• Active autoimmune disease that may worsen while receiving immunostimulants.
• Known history of positive HIV test or known acquired immunodeficiency syndrome.
• Patients who are using immunosuppressive agents, except for the following conditions:
• Intranasal, inhaled, topical steroids, or topical steroid injections (eg, intra-articular injections);
• Physiological doses of systemic corticosteroids ≤10 mg/day prednisone or equivalent;
• Steroids used to prevent allergic reactions (eg, before CT scan).

Sponsors & Collaborators

• Sir Run Run Shaw Hospital: lead

Study Sites (1)

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China

RECRUITING

MeSH Terms

Conditions

Rectal Neoplasms

Interventions

envafolimab

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases

Study Officials

• sheng dai

  Sir Run Run Shaw Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sheng Dai, MD&PhD

CONTACT

13575472669; daimd@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, head of medical affairs

Model Details: The 54 enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery). The other 54 patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).

Study Record Dates

• First Submitted: February 20, 2023
• First Posted: March 2, 2023
• Study Start: April 1, 2023
• Primary Completion: April 1, 2025
• Study Completion (Estimated): December 1, 2028
• Last Updated: May 8, 2023

Record last verified: 2023-05

Locations

CN (1)